• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMM 1.49% 34.0¢

IMMUTEP LIMITED

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company... Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
IMM 14:09 7 2.1K
14:09 Last post  Joe007 Comments Created with Sketch.  7  Views Created with Sketch.  2.1K 
IMM 13:16 15 6.8K
13:16 Last post  ahjay Comments Created with Sketch.  15  Views Created with Sketch.  6.8K 
IMM 11:17 42 21K
11:17 Last post  coolkiat Comments Created with Sketch.  42  Views Created with Sketch.  21K 
IMM
Overnight Market report
45 46 47
06:30 2.8K 1.1M
06:30 Last post  ahjay Comments Created with Sketch.  2.8K  Views Created with Sketch.  1.1M 
IMM 24/07/24 17 8.7K
24/07/24 Last post  Joe007 Comments Created with Sketch.  17  Views Created with Sketch.  8.7K 
IMM
News: IMM Immutep Announces Successful Meeting With FDA On TACTI-004 Phase III Trial Design
22/07/24 0 280
22/07/24 Last post  Hot News Comments Created with Sketch.  0  Views Created with Sketch.  280 
IMM
News: IMM Immutep Announces Positive Feedback Received From US FDA
22/07/24 0 263
22/07/24 Last post  Hot News Comments Created with Sketch.  0  Views Created with Sketch.  263 
IMM
Media
2
20/07/24 99 45K
20/07/24 Last post  Joe007 Comments Created with Sketch.  99  Views Created with Sketch.  45K 

See All Discussions arrow Created with Sketch.

Timeline

Change in substantial holding
26 Jul 16:43
 
Successful Meeting with FDA on Phase III Design in NSCLC
22 Jul 08:12
 
Regulatory Clearance received for Phase 1 trial of IMP761
17 Jul 08:48
 
Becoming a substantial holder
12 Jul 15:51
 
Positive results in TACTI-003 for 1L HNSCC cohort B patients
12 Jul 08:26
 
Webcast to discuss data presented at ESMO Plenary Session
12 Jul 08:26
 
View More arrow Created with Sketch.
(20min delay)
Last
34.0¢
Change
0.005(1.49%)
Mkt cap ! $493.8M
Open High Low Value Volume
33.5¢ 34.0¢ 33.0¢ $1.220M 3.642M

Buyers (Bids)

No. Vol. Price($)
3 57289 33.0¢
 

Sellers (Offers)

Price($) Vol. No.
34.0¢ 52306 3
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
Last
33.0¢
  Change
0.005 ( 1.23 %)
Open High Low Volume
33.3¢ 34.0¢ 32.8¢ 1093425
Last updated 15.59pm 26/07/2024 ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.